KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2018.11

  -

  Present

  慶應義塾大学薬学部, 医薬品情報学講座, 助教

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 2010.04

  -

  2014.03

  The University of Tokyo, 薬学部, 薬科学科

  University, Graduated

• 2014.04

  -

  2016.03

  The University of Tokyo, 薬学系研究科, 薬科学専攻

  Graduate School, Completed, Master's course

• 2016.09

  The University of Tokyo, 薬学系研究科, 薬科学専攻

  Graduate School, Doctoral course

• 2017.09

  The University of Tokyo, 薬学系研究科, 薬学専攻

  Graduate School, Doctoral course

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士（薬科学）, The University of Tokyo, Dissertation, 2024.10

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• 東京大学フューチャーファカルティプログラム修了, 大学教員としてのキャリアを進むにあたり不可欠となる教育力の向上をめざすプログラム, 2017.03

• 薬剤師免許, 2019

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Clinical pharmacy

• Life Science / Medical management and medical sociology

Research Keywords 【 Display / hide 】

Research Keywords 【 Display / hide 】

• 介護施設

• 医療安全

• 医薬品情報

• 多職種連携

• 薬剤師

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• Protective Effect of Vitamin E Against Vancomycin-Induced Nephrotoxicity: A Large-Scale Electronic Medical Record Study From Japan

  Nakanishi S., Imai S., Saito M., Kizaki H., Iino H., Tsuchiya M., Hori S.

  Basic and Clinical Pharmacology and Toxicology 138 ( 6 ) e70245 2026.06

  ISSN  17427835

  　View Summary

  Vancomycin (VCM) is essential for treating methicillin-resistant Staphylococcus aureus infections, but its use is limited by vancomycin-induced nephrotoxicity (VIN). Although preclinical and small clinical studies suggest a protective role for vitamin E, real-world evidence remains limited. We conducted a retrospective cohort study using a large-scale Japanese electronic medical record database including adult patients who received intravenous VCM between 1996 and 2022. VIN was defined according to Kidney Disease Improving Global Outcomes criteria. The association between concomitant vitamin E use and VIN was evaluated using propensity score matching based on logistic regression and light gradient boosting machine models, followed by Kaplan–Meier analysis and Cox proportional hazards regression. Robustness was examined using three analytical strategies, including adjustment for concomitant medications. Among 12 411 eligible patients, 2267 (18.3%) developed VIN and 116 (0.9%) received vitamin E. After matching, vitamin E use was associated with a 10% lower incidence of VIN. Kaplan–Meier analysis showed significantly lower cumulative incidence in the vitamin E group in two approaches. Across 63 Cox models, vitamin E consistently demonstrated a protective trend. These findings support the potential preventive role of vitamin E in maintaining VCM therapy.

  • Access to Document (DOI)

• Maternal and neonatal outcomes of antithrombotic therapy in pregnant women with valvular or complex congenital heart disease: a nationwide retrospective cohort study in Japan

  Yanagisawa Y., Tsuchiya M., Imai S., Kizaki H., Hori S.

  European Journal of Clinical Pharmacology 82 ( 5 )  2026.05

  ISSN  00316970

  　View Summary

  Purpose: Certain women with heart disease require lifelong antithrombotic therapy. However, the impact of such therapy during pregnancy on maternal and neonatal outcomes remains unclear. This study aimed to investigate the prescription patterns and clinical outcomes associated with antithrombotic therapy in pregnant women with heart disease. Methods: Using a Japanese administrative claims database, we identified pregnant women diagnosed with valvular heart disease or complex congenital heart disease between January 2008 and July 2023. In this retrospective observational study, we compared maternal clinical outcomes between women who were prescribed antithrombotic drugs during pregnancy and those who were not. For infants who could be linked to their mothers in the database, neonatal outcomes were also assessed. Results: A total of 550 pregnant women with a history of heart disease were identified, of whom 90 (16.4%) received antithrombotic therapy during pregnancy. Women who received antithrombotic therapy had a higher proportion of cesarean delivery (90.0% vs. 49.8%, p < 0.001). Intensive care unit (ICU) admission rate was significantly higher in this group (24.4% vs. 10.5%, p < 0.001), as was critical obstetric bleeding (13.3% vs. 1.7%, p = 0.009). No in-hospital maternal deaths or fatal arrhythmias were observed. Among the neonates associated with their mothers, a total of 238 were identified. Admission to a neonatal ICU was significantly more frequent among infants born to women who received antithrombotic therapy (35.7% vs. 13.3%, p = 0.001). Conclusion: Although careful maternal and neonatal management is necessary, no in-hospital maternal deaths or severe cardiovascular events were observed among women prescribed antithrombotic therapy. This study provides valuable evidence to inform clinical decision-making in pregnant women with valvular heart disease requiring antithrombotic therapy in Japan.

  • Access to Document (DOI)

• Laxative use and acute kidney injury risk: Analysis of a Japanese hospital-based database.

  Mitsuboshi S, Tsuchiya M, Kizaki H, Hori S, Imai S

  The Journal of pharmacology and experimental therapeutics 393 ( 3 ) 104300 2026.03

  ISSN  0022-3565

  • Access to Document (DOI)

• 医薬品適正使用を支援する一般市民向けすごろく型学習プログラムの開発と実践　お薬手帳活用を題材とした動機づけ設計

  板倉 理子, 木崎 速人, 岡澤 優太, 土屋 雅美, 今井 俊吾, 堀 里子

  医療薬学 ((一社)日本医療薬学会)  52 ( 3 ) 151 - 160 2026.03

  ISSN  1346-342X

  　View Summary

  attention、relevance、confidence、satisfaction(ARCS)モデルに基づいて、お薬手帳の主体的活用をテーマとした学習プログラム(すごろく形式)を設計・開発し、医薬品を服用している研究対象者11名(男性4名、50～70歳代10名)に実施してもらった。プログラム実施直前、実施直後、実施後1ヵ月に医薬品の適正使用に対する意識や行動の変化を調査し、ARCSモデルの4要素について5段階セマンティック・デファレンシャル法により評価した。その結果、平均評点4点以上であった。プログラム実施前後で参加者のお薬手帳の活用を含む医薬品適正使用に関連する意識と行動意欲の向上がみられ、一部の参加者では実際の行動変容も観察された。動機づけ設計を基盤とする本アプローチは、一般市民の主体的な健康管理への関与を促す有効な手段となり得ることが示唆された。

• A scalable natural language processing framework for drug repurposing in chemotherapy-induced adverse events from clinical narrative records

  Tsuchiya M., Inoue M., Kawazoe Y., Shimamoto K., Seki T., Imai S., Kizaki H., Shinohara E., Yada S., Wakamiya S., Aramaki E., Hori S.

  European Journal of Cancer 232   116157 2026.01

  ISSN  09598049

  　View Summary

  Background Preventing chemotherapy-related adverse events (AEs) remains an unmet clinical challenge. Preclinical studies have suggested protective effects of several existing agents, but translation into human evidence has been limited. We aimed to establish proof of concept (PoC) for drug repurposing by applying a natural language processing (NLP)-based framework to electronic health record (EHR) narratives, thereby bridging preclinical findings with clinical validation. Methods We retrospectively analyzed 56,326 patients with cancer treated at the University of Tokyo Hospital (2004–2023). A transformer-based NLP model extracted symptomatic AEs from clinical notes. Candidate preventive drugs identified from preclinical evidence were assessed using propensity score matching and Cox proportional hazards models. We evaluated angiotensin II receptor blockers (ARBs) for fluoropyrimidine-induced oral mucositis and ramelteon for platinum-induced peripheral neuropathy, with laxatives serving as a negative control. Results NLP demonstrated high accuracy (precision 0.81–0.83; recall 0.95–0.97). After matching, ARB co-administration was significantly associated with reduced mucositis incidence (hazard ratio [HR] 0.58, 95 % confidence interval [CI] 0.44–0.77; P < 0.001), representing a clinical PoC consistent with mechanistic preclinical data. Ramelteon showed an exploratory protective signal against neuropathy (HR 0.60, 95 % CI:0.38–0.93; P = 0.024). No preventive association was observed for laxatives. Conclusions This study introduces a scalable NLP-epidemiology framework for non-invasive, real-world validation of drug repurposing candidates. The ARB finding provides human-level PoC evidence supporting prospective clinical testing, while the ramelteon signal warrants further exploration. Our approach demonstrates how EHR narratives can operationalize translational research, prioritizing safe, accessible agents for improving the tolerability of cancer treatment.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Development of an incident reporting support system for medication-related incidents in long-term residential care facilities

  Kizaki, Hayato

  学事振興資金研究成果実績報告書 (慶應義塾大学)  2023

• Development of a fall risk assessment tool for the prevention of falls in nursing homes in Japan.

  Kizaki, Hayato

  学事振興資金研究成果実績報告書 (慶應義塾大学)  2020

Reviews, Commentaries, etc. 【 Display / hide 】

Reviews, Commentaries, etc. 【 Display / hide 】

• 新薬まるわかり アウィクリ注フレックスタッチ総量300単位/700単位 (インスリンイコデク)

  木﨑速人，佐藤宏樹，三木晶子著　堀 里子，澤田康文監.

  日経ドラッグインフォメーション ( 日経BP社)  329 2025.03

  Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

• 新薬まるわかり フォゼベル 5mg/10mg/20mg/30mg（テナパノル塩酸塩）

  木﨑速人，平井理夏，佐藤宏樹，三木晶子著　堀 里子，澤田康文監.

  日経ドラッグインフォメーション ( 日経BP社)  327 2025.01

  Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

• 新薬まるわかり レクビオ皮下注 300 mg シリンジ（インクリシランナトリウム）

  木﨑速人，清水海人，佐藤宏樹，三木晶子著　堀 里子，澤田康文監.

  日経ドラッグインフォメーション ( 日経BP社)  325 2024.11

  Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

• 新薬まるわかり リットフーロカプセル 50mg（リトレシチニブトシル酸塩）

  木﨑速人，出雲真帆，佐藤宏樹，三木晶子著　堀 里子，澤田康文監.

  日経ドラッグインフォメーション ( 日経BP社)  323 2024.09

  Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

• 新薬まるわかり マンジャロ皮下注2.5mg/5mg/7.5mg/10mg/12.5mg/15mgアテオス（チルゼパチド）

  木﨑速人，出雲真帆，佐藤宏樹，三木晶子著　堀 里子，澤田康文監.

  日経ドラッグインフォメーション ( 日経BP社)  321 2024.07

  Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• Development of an Automated Classification System for Medication-Related Incident Factors: A Practical Approach to Enhancing Patient Safety Management.

  Takamatsu Y, Ebara S, Kizaki H, Watabe S, Imai S, Yada S, Aramaki E, Yasumuro O, Funakoshi R, Hori S.

  [International presentation]  Medinfo 2025, 

  2025.08

  , 

  Oral presentation (general)

• Natural Language Processing-Based Approach to Detect Common Adverse Events of Anticancer Agents from Unstructured Clinical Notes: A Time-to-Event Analysis. Stud Health Technol Inform.

  Tsuchiya M, Shimamoto K, Kawazoe Y, Shinohara E, Yada S, Wakamiya S, Imai S, Kizaki H, Hori S, Aramaki E.

  [International presentation]  Medinfo 2025, 

  2025.08

  , 

  Oral presentation (general)

• マスメディアの「医薬品」に関する報道が患者に及ぼす影響

  佐々木愛、今井俊吾、阿部真也、松井　洸、小野貴登、卯田健太、佐山杏子、木﨑速人、山口　浩、堀　里子、野村和彦

  [Domestic presentation]  第27回日本医薬品情報学会総会・学術大会, 

  2025.07

  , 

  Oral presentation (general)

• 課題研究班実施時の経験紹介1　～大学院生/大学教員として携わった立場から

  木﨑速人

  [Domestic presentation]  第27回日本医薬品情報学会総会・学術大会, 

  2025.07

  , 

  Symposium, workshop panel (public)

• 自然言語処理を用いた類似インシデント事例検索システムの開発

  久村颯海、木﨑速人、土屋雅美、今井俊吾、西山智弘、矢田竣太郎、荒牧英治、安室修、舟越亮寛、堀　里子

  [Domestic presentation]  日本医療薬学会 第8回 フレッシャーズ・カンファランス, 

  2025.06

  , 

  Oral presentation (general)

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• 自然言語処理による薬剤安全管理の統合的評価手法開発

  2026

  -

  2027

  上原記念生命科学財団, 海外留学助成金, Research grant, Principal investigator

• 大規模言語モデル（LLM）活用による薬学生の省察的実践を促す対話型学習支援システムの開発

  2025.12

  -

  2026.11

  公益財団法人カシオ科学振興財団, Principal investigator

• Research on Multimodal Analysis of Voice and Language Information in Medication Counseling and its Application to Effective Guidance Methods and Educational Support

  2025.04

  -

  2026.03

  British Council, RENKEI workshop award grants, Rafael MESTRE, Research grant, Collaborating Investigator(s) (not designated on Grant-in-Aid)

  　View Remarks

  配分額は日本円の概算額（Full amount of 6000GBP）

• 薬局におけるPHR活用方法とその推進に関する実証的研究

  2025.04

  -

  2027.03

  厚生労働科学研究費補助金, 医薬品・医療機器等レギュラトリーサイエンス政策研究事業, Research grant, Coinvestigator(s)

• Establishment of a foundation for optimizing risk management of medical incidents based on collaboration between non-medical and medical professionals

  2024.04

  -

  2027.03

  Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  　View Summary

  介護場面での患者安全の実現のためには，介護者（非医療専門家）や医療者が発信する患者情報に基づくリスク管理の最適化が重要である．本研究では，こうした情報（主にテキスト情報）を活用して，医療インシデントのリスク管理において重要な情報を抽出する自然言語処理（Natural Language Processing, NLP）モデルを開発する．ここで得たNLPモデルを，リスク管理における重要情報の抽出と集約に活用し，介護職と医療職の連携に基づくリスク管理の最適化を促すシステム構築に取り組む．本研究は，介護関連情報の利活用を推進させるとともに，介護場面における医療インシデントのリスク管理の最適化に大きく貢献することが期待される．

display all >>

Awards 【 Display / hide 】

Awards 【 Display / hide 】

• 第35回日本医療薬学会年会 優秀演題賞

  木﨑速人，吉川康大，河野広太郎，上村忠聖，鈴木信也，佐村　優，廣瀬直樹，永野靖典，林　誠一，土屋雅美，今井俊吾，堀　里子, 2025.11, 日本医療薬学会, 濁音・半濁音を考慮した新規薬名類似度指標の開発と調剤場面での薬剤取り違えリスク評価への応用検討

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 第35回日本医療薬学会年会 優秀演題賞

  三星　知，今井俊吾，木崎速人，堀　里子, 2025.11, 日本医療薬学会, ランソプラゾールとセフトリアキソンの併用に伴う心室性不整脈および心停止リスク-JMDC医療機関データベースの解析

  Type of Award： Award from Japanese society, conference, symposium, etc.

• 第19回日本ファーマシューティカルコミュニケーション学会大会 優秀演題賞

  薬剤師に相談するための質問リスト（QPLP）の活用可能性に関する患者へのインターネットパネル調査, 2025.09, 早川雅代、木﨑速人、土屋雅美、柳澤友希、今井俊吾、鈴木信行、香川由美、堀　里子

  Type of Award： Award from Japanese society, conference, symposium, etc.

• Best Paper Award at MedInfo 2025

  Masami Tsuchiya, Kiminori Shimamoto, Yoshimasa Kawazoe, Emiko Shinohara, Shuntaro Yada, Shoko Wakamiya, Shungo Imai, Hayato Kizaki, Satoko Hori, Eiji Aramaki, 2025.08, Natural Language Processing-Based Approach to Detect Common Adverse Events of Anticancer Agents from Unstructured Clinical Notes: A Time-to-Event Analysis

  Type of Award： Award from international society, conference, symposium, etc.

• 2024年度 日本医薬品情報学会 論文賞

  森部詩月，今井俊吾，佐山杏子，上村忠聖，林　誠一，木﨑速人，堀　里子, 2025.07, 薬名類似に起因する薬剤誤処方の傾向分析 ‐薬剤師による誤調剤事例との比較‐

  Type of Award： Honored in official journal of a scientific society, scientific journal

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• EVIDENCE-BASED MEDICINE

  2026

• PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

  2026

• EARLY EXPOSURE TO HOSPITAL & COMMUNITY PHARMACY

  2026

• PRE-CLINICAL TRAINING IN PRESCRIPTION PROCESSING FOR HOSPITAL & COMMUNITY PHARMACY

  2026

• ENGLISH EXERCISES FOR PHARMACEUTICAL SCIENCES

  2026

display all >>

Courses Previously Taught 【 Display / hide 】

Courses Previously Taught 【 Display / hide 】

• 実務実習事前学習（実習）

  Keio University

  2018.04

  -

  2019.03

  , 

  Autumn Semester, Laboratory work/practical work/exercise, 160people

Educational Activities and Special Notes 【 Display / hide 】

Educational Activities and Special Notes 【 Display / hide 】

• 明治大学 「教職実践演習」：「教育実習の総まとめ」、授業題目：正しい薬の育て方

  2017.11

  , Special Affairs

• 東京大学教養学部 全学自由研究ゼミナール「伝えるを学ぼう」：第6回「大学院生による模擬授業・検討・解説３」、授業題目：創る薬から育てる薬へ

  2017.05

  , Special Affairs

• 学校法人河合塾 知の追究講座 講師：「薬の創り方・育て方〜薬学研究の最前線〜」

  2017.04

  , Special Affairs

• 東京大学文学部 第1回留学生ワークショップ 講師：「何気ない日本人の習慣・考え方を学ぼう！」

  2017.03

  , Special Affairs

• 学校法人河合塾 学びみらいプログラム 講師：「正しい薬の育て方」

  2017.03

  , Special Affairs

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• 日本薬学会, 

  2020

  -

  Present

• 医薬品情報学会

  　

• 医療薬学会

  　

Committee Experiences 【 Display / hide 】

Committee Experiences 【 Display / hide 】

• 2020.04

  -

  Present

  研究企画委員会 委員, 一般財団法人　日本医薬品情報学会